High intensity focused ultrasound, or HIFU, is a minimally invasive treatment option for localized prostate cancer that may offer a balance between eliminating cancer and maintaining quality of life. HIFU with Sonablate® 500 (Sonablate HIFU) is an out-patient, radiation-free procedure.
The HIFU procedure may be an option for men diagnosed with organ-confined prostate cancer. During the procedure, precisely focused ultrasound waves raise the temperature of the targeted prostate tissue to 195 degrees Fahrenheit in 2-3 seconds. This rapid-firing heat destroys the targeted tissue while leaving structures outside the targeted tissue unharmed.
Explore our website to understand more about prostate cancer and Sonablate HIFU.
The Sonablate® 500 is approved for investigational use only within the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S.
International HIFU’s treatment centers enable U.S. patients access to HIFU technology for prostate cancer in locations where it is available for use including Nassau, Bahamas; Cancun and Puerto Vallarta, Mexico; Bermuda; and Winnipeg, Canada.
Miracle cancer cure in the Bahamas
THonline.com, June 2013
read moreDoctors Hospital featured on Larry King Show
thebahamasweekly.com, April 2013
read moreRoundtable Discussion
Touch Medical, European Urological Review, Dec 2012
read moreData show low morbidity of HIFU in short-term trials
Urology Times, May 1, 2012
read more
My wife and I went to Cancun several days early and had a vacation prior to the procedure. Saturday arrived and we were picked up at the hotel that the HIFU folks had arranged for us, the Ritz Carlton. I arrived at the hospital at 10:30, was prepped, walked into the actual procedure room, lay on the table, and woke up!
More patient stories»
Treatment for prostate cancer with the Sonablate® 500 (Sonablate HIFU) is commercially available in over 30 countries. The Sonablate® 500 (Sonablate) is only approved for investigational use within the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. The FDA has made no decision as to the safety or efficacy of the Sonablate for the treatment of prostate cancer. If the Sonablate is approved by the FDA for use in the U.S., there is no assurance that instructions for use or the specifications of the device will be the same as the device and treatment approved or authorized in other countries outside of the U.S.
The information provided on this website is for general information purposes only and is not intended to replace sound professional medical advice and care. All treatment options and potential outcomes and complications should be discussed with a qualified healthcare provider.